La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
GlaxoSmithKline Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 5/6
GlaxoSmithKline Pharmaceuticals ha un patrimonio netto totale di ₹17.8B e un debito totale di ₹186.7M, che porta il suo rapporto debito/patrimonio netto a 1.1%. Le sue attività totali e le sue passività totali sono rispettivamente ₹35.6B e ₹17.8B. L'EBIT di GlaxoSmithKline Pharmaceuticals è ₹9.3B rendendo il suo rapporto di copertura degli interessi -13. Ha liquidità e investimenti a breve termine pari a ₹18.6B.
Informazioni chiave
1.1%
Rapporto debito/patrimonio netto
₹186.65m
Debito
| Indice di copertura degli interessi | -13x |
| Contanti | ₹18.57b |
| Patrimonio netto | ₹17.78b |
| Totale passività | ₹17.79b |
| Totale attività | ₹35.57b |
Aggiornamenti recenti sulla salute finanziaria
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02Recent updates
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?
Jul 07Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( ₹28.0B ) di GLAXO superano le sue passività a breve termine ( ₹15.2B ).
Passività a lungo termine: Le attività a breve termine di GLAXO ( ₹28.0B ) superano le sue passività a lungo termine ( ₹2.5B ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: GLAXO ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di GLAXO è aumentato da 0.03% a 1.1% negli ultimi 5 anni.
Copertura del debito: Il debito di GLAXO è ben coperto dal flusso di cassa operativo ( 3118.2% ).
Copertura degli interessi: GLAXO matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.